You are here

Global

Chinese official acknowledges the country's vaccines’ effectiveness is low

BEIJING (AP) — In a rare admission of the weakness of Chinese coronavirus vaccines, the country’s top disease control official says their effectiveness is low and the government is considering mixing them to get a boost.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

AstraZeneca: Blot Clots apparently Stem From Rare Antibody Reaction

New research has identified unusual antibodies that appear to have caused, in rare cases, serious and sometimes fatal blood clots in people who received the Covid vaccine made by AstraZeneca.

Exactly why the rare reactions to the vaccine occurred is still a mystery.

Scientific teams from Germany and Norway found that people who developed the clots after vaccination had produced antibodies that activated their platelets, a blood component involved in clotting. The new reports add extensive details to what the researchers have already stated publicly about the blood disorder.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Vaccine shortages hit poor countries, affecting at least 60 nations

LONDON (AP) — As many as 60 countries, including some of the world’s poorest, might be stalled at the first shots of their coronavirus vaccinations because nearly all deliveries through the global program intended to help them are blocked until as late as June.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Scientists are trying to find a simple pill to treat Covid-19 ...but

The world has vaccines that can prevent most cases of Covid-19. It even has drugs that can help with the most serious symptoms of the disease. Now what it needs is a Tamiflu for SARS-CoV-2.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Rise of Variants in Europe adds to coronavius dangers

Europe, the epicenter of the coronavirus pandemic last spring, has once again swelled with new cases, which are inundating some local hospitals and driving a worrisome global surge of Covid-19.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Moderna’s COVID-19 vaccine provides antibodies for at least 6 months after the second dose but fades for older persons

Antibodies persisted 6 months after the second dose of Moderna's COVID-19 vaccine in younger and middle-age adults, but were diminished in older adults when using more sensitive assays, according to data from an ongoing phase I trial.

Country / Region Tags: 
Problem, Solution, SitRep, or ?: 

Pages

Subscribe to Global
howdy folks